Recent Advances in the Clinical Development of First- and Best-in-Class ADCs: Pipeline Update from...
Recent Advances in the Clinical Development of First- and Best-in-Class Antibody-Drug Conjugates: Pipeline Update from Adcendo
ZW191: A Next-Generation FRα-Targeted ADC Demonstrates Promising Efficacy and Safety in Advanced Solid Tumors
ZW191: A Next-Generation FRα-Targeted ADC Demonstrates Promising Efficacy and Safety in Advanced Solid Tumors
AACR 2026: Preclinical Advances in Bispecific and Novel ADCs
At the annual meeting of the American Association for Cancer Research (AACR), held April 17 - 22, 2026, in San Diego, CA., new preclinical data will be presented for three proprietary antibody-drug conjugate (ADC) assets—CS5007 (EGFR/HER3 ADC), CS5006 (ITGB4 ADC), and CS5008 (DLL3/SSTR2 ADC)—being developed by CStone Pharmaceuticals.
AACR 2026: QLS5132, a CLDN6-Targeted ADC, Demonstrates Clinical Benefit in Advanced Platinum-Resistant Ovarian Cancer
Patients treated with QLS5132, a novel antibody-drug conjugate (ADC) developed by Qilu Pharmaceutical Co. experienced clinical benefit. This conclusion is based on results from a phase 1 clinical study presented at the annual meeting of the American Association for Cancer Research, held April 17 - 22. 2026, in San Diego Ca.
Mocertatug Rezetecan Shows Promising Results in Treatment of Platinum-Resistant Ovarian and Endometrial Cancers
B7-H4 (also known as B7 homolog 4, B7S1, or VTCN1) is an immunoregulatory ligand in the B7-CD28 family, notable for its overexpression in multiple tumor types, including breast, ovarian, uterine, and lung cancers. B7-H4 suppresses T-cell effector functions, including inflammatory cytokine production and cytolytic activity, and promotes the polarisation of naïve CD4 T-cells into induced Tregs, invasion, and metastasis, correlating with poor prognosis in advanced tumors. Its restricted expression in normal tissues and tumor-promoting roles make B7-H4 an attractive target for tumor-selective therapies such as antibody-drug conjugates (ADCs). B7-H4 has attracted credible attention from drug developers because it is highly expressed in immune 'cold' tumors, in which PD-1 and PD-L1 are minimally expressed, making these tumors unresponsive to most currently used immunotherapies.
Phase 1/2 Data for JK06, a 5T4-Targeted Antibody-Drug Conjugate, Shows Promising Results
Data from a Phase 1/2 dose-escalation and expansion study of JK06, a 5T4-targeted antibody-drug conjugate (ADC) being developed by SalubrisBio, have shown promising results...
Preclinical Evaluation of BD200 – a First-in-Class Multibody-Drug Conjugate Targeting Trop-2 and Nectin-4
Antibody-drug conjugates (ADCs) have become a mainstay in targeted cancer therapies, but their effectiveness can be limited by tumor antigen heterogeneity and acquired resistance.
AACR 2026: Pioneering the Next Generation of Targeted Cancer Therapies
The landscape of cancer treatment is rapidly evolving, driven by relentless innovation and a deepening understanding of tumor biology. Among the leading developers in this revolution is Byondis, an independent Dutch biopharmaceutical company with a bold mission: to deliver breakthrough solutions for patients with cancer through the creation of innovative, targeted medicines.
AACR 2026: Conjugates Take Center Stage in Precision, Partnership, and Purpose-Driven Cancer Research
Antibody-drug conjugate (ADC) innovation continues at a remarkable pace, as evidenced by the 2026 Annual Meeting of the American Association for Cancer Research (AACR), held...
U.S. FDA Clears Investigational New Drug Application for a Phase 1/2 Study of OBI-902,...
The U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for OBI-902, a Trophoblast cell surface antigen 2 (TROP2-) targeting ADC (see ADC Drugmap) being developed by OBI Pharma.
